Biocon Limited

Biocon Addresses Media Rumors Regarding Biocon Biologics Merger

Biocon addresses media rumors about merging Biocon Biologics, stating a committee is evaluating options with consideration for legal, tax, and regulatory factors. No immediate disclosures are required.

Biocon Limited Announces Financial Results for Quarter and Half-Year Ended September 30, 2025

Biocon Limited has announced its financial results for the quarter and half-year ended September 30, 2025, with details published in leading newspapers and available on the company's website.

Biocon releases Q2 FY26 Earnings Call audio and video recordings

Biocon Limited has published the audio and video recordings of its Q2 FY26 Earnings Call, held on November 12, 2025, on its investor relations website for shareholder access.

Biocon Limited Announces Q2 FY26 Earnings Call and Performance Overview

Biocon Limited announces Q2 FY26 results with revenue growth across Biosimilars, Generics, and CRDMO. Earnings call scheduled for November 12, 2025.

Biocon Limited: Monitoring Agency Report for Quarter Ended September 30, 2025

Biocon Limited submits Monitoring Agency Report for the quarter ended September 30, 2025, as reviewed by the Audit Committee and Board of Directors on November 11, 2025.

Biocon Q2FY26 Operating Revenue Up 20% to ₹4,296 Cr

Biocon's Q2FY26 operating revenue rose 20% to ₹4,296 crore. EBITDA increased 29% to ₹928 crore, and PBT surged 153% to ₹183 crore. An earnings call is scheduled for 12th November 2025.

Biocon Board approves Q2 FY26 results, redeems NCDs, acquires CCDs & issues Commercial Papers

Biocon board approves Q2 FY26 results, early redemption of NCDs aggregating to ₹500 crore, acquisition of CCDs of Biocon Biologics Limited aggregating to ₹300 crore and issuance of commercial papers up to ₹550 crore.

Biocon Board Approves Q2 FY26 Results, ₹500 Cr NCD Redemption, and ₹300 Cr BBL CCD Acquisition

Biocon's board approved Q2 FY26 results, early redemption of ₹500 Cr NCDs by January 31, 2026, and acquisition of ₹300 Cr BBL CCDs by January 30, 2026. Also approved ₹550 Cr Commercial Papers issuance.

Biocon Board Approves Q2 FY26 Results, ₹500 Cr NCD Redemption, ₹300 Cr BBL CCD Acquisition, and ₹550 Cr CP Issuance

Biocon's board approved Q2 FY26 results, ₹500 crore NCD redemption by Jan 31, 2026, ₹300 crore BBL CCD acquisition by Jan 30, 2026, and ₹550 crore Commercial Paper issuance.

Biocon Board Approves Q2 Results, Early NCD Redemption, CCD Acquisition, and CP Issuance

Biocon's board approved strong Q2FY26 results with increased profits, early redemption of ₹500 crore NCDs, acquisition of ₹300 crore CCDs in Biocon Biologics, and issuance of ₹550 crore Commercial Papers.

Biocon Board Approves Q2 Results, ₹500 Cr NCD Redemption, ₹300 Cr BBL CCD Acquisition, and ₹550 Cr CP Issuance

Biocon's Board approved Q2 FY26 financial results, early redemption of ₹500 Crores NCDs, acquisition of ₹300 Crores BBL CCDs, and issuance of ₹550 Crores Commercial Papers.

US FDA Inspection at Biocon's Vizag API Facility Concludes with Two Observations

Biocon's Vizag API facility underwent a US FDA inspection from November 3-7, 2025, resulting in two observations. The company will address these and anticipates no business impact.

Biocon Limited Announces Q2 FY 2025-26 Earnings Conference Call on 12 Nov 2025

Biocon Limited is organizing an earnings conference call for Q2 FY 2025-26 financial results on November 12, 2025, at 09:00 hrs IST. Details are available on the company website.

ICRA Reaffirms Biocon's Long-Term and Short-Term Credit Ratings

ICRA reaffirms Biocon's credit ratings at [ICRA]AA+(Stable)/[ICRA]A1+ due to diversified business and improved financials after strategic financial actions and revenue growth, expecting sustained performance and deleveraging.

Biocon Biologics UK Limited re-registered as Public Limited Company

Biocon Biologics UK Limited, a step-down subsidiary of Biocon, has been re-registered as a Public Limited Company and its name changed to Biocon Biologics UK PLC effective October 29, 2025.

Biocon Limited announces change in name of step-down subsidiaries

Biocon Limited announced the name change of its step-down subsidiaries, effective October 21, 2025. BIOCON BIOLOGICS UK LIMITED is now BIOCON BIOLOGICS INTERNATIONAL LIMITED and BIOSIMILARS NEWCO LIMITED is now BIOCON BIOLOGICS UK LIMITED.

Biocon Biologics Receives Health Canada Approval for Biosimilar Yesintek™

Biocon Biologics received Health Canada approval for Yesintek™, a biosimilar to Stelara®, for autoimmune conditions. This expands their North American presence with an affordable treatment option.

Biocon Biologics and Civica Expand Partnership, Launch Insulin Glargine

Biocon Biologics partners with Civica to launch private-label Insulin Glargine, expanding access to affordable diabetes treatment options in the U.S.

Biocon's New US Facility Receives FDA Observation, No Business Impact Expected

Biocon's new U.S. manufacturing site in Cranbury, New Jersey, received one U.S. FDA observation during a GMP inspection, with no expected impact on business operations.

Biocon Limited to participate in Nomura Asian Credit Corporate Day 2025

Biocon's management will attend the Nomura Asian Credit Corporate Day 2025 on October 17, 2025, for virtual group meetings, without disclosing UPSI.

Biocon Announces Change in Trustee for Employees Welfare Trust

Biocon Limited announced an amendment to its Employees Welfare Trust Deed, reflecting a change in trustee. Ms. Renuka Ganesh resigned, and Ms. Maninder Kapoor Puri was appointed, effective October 09, 2025.

Biocon Pharma receives tentative U.S. FDA approval for Rifaximin Tablets, 550 mg

Biocon Pharma, with Carnegie Pharmaceuticals, received tentative U.S. FDA approval for Rifaximin Tablets, 550 mg, indicated for hepatic encephalopathy recurrence and irritable bowel syndrome with diarrhea.

Biocon Board Approves Early Redemption of NCDs worth ₹1,070 Crore

Biocon Biologics Secures October 1, 2025, U.S. Launch Date for Denosumab Biosimilars Bosaya™ and Aukelso™

Biocon Receives Show Cause Notice from Commercial Taxes Department

Biocon Biologics' Yesafili® Receives Public Funding in Ontario, Canada for Retinal Diseases

Biocon announces record date for buyback of ₹600 crore Commercial Paper

Biocon Biologics Gets U.S. FDA Nod for Denosumab Biosimilars, Bosaya™ and Aukelso™

Biocon informs shareholders about unclaimed dividends and KYC update

Biocon Foundation Supports Government High School, Inaugurates New Building

Biocon Inaugurates First U.S. Manufacturing Facility in New Jersey with ₹250 Crore Investment

Biocon informs shareholders about 'Saksham Niveshak' campaign

Biocon Appoints Rajesh Shanoy as Company Secretary and Compliance Officer

Biocon to participate in Jefferies and J.P. Morgan investor conferences in September 2025

Biocon to meet with Morgan Stanley at Global Healthcare Conference

U.S. FDA completes inspection at Biocon Biologics' Bengaluru facility, issues 5 procedural observations

Biocon to meet with Analysts/Institutional Investors on 5 Sept 2025

Biocon Limited to Attend Motilal Oswal 21st Annual Global Investor Conference

Biocon Pharma gets tentative US FDA nod for Sitagliptin Tablets

Biocon Announces 'Saksham Niveshak' Campaign Awareness

Biocon reports sharp decline in Q1 FY26 consolidated profit and total comprehensive income

Biocon Reports Steady Growth in FY25, Expands GLP-1 & Biosimilars Portfolio, and Secures Significant Funding

Biocon Foundation and IISc Commemorate World Head & Neck Cancer Day, Announce White Paper and New Guidelines

Deepali Naair Appointed as Global Head - Brand & Corporate Communications at Biocon Biologics

Biocon Biologics Launches Nepexto®, a Biosimilar to Enbrel®, in Australia